Moderna releases positive interim phase I data from its clinical trial of its mRNA 1273 vaccine against SARS-CoV-2

Company said that these interim phase I data demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25ug. A phase II trial will now be modified to evaluate two dose levels, 50ug and 100ug.


Biospace Inc.